person · Reporting owner
Bedoya-Toro Munera Maria E
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | SVP, Regulatory Affairs | February 17, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dermata Therapeutics, Inc.
Report date February 17, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,012 |
Reported balance
After 2026-02-17 transaction · row 1
1 source rowRow 1 · 2026-02-17 · Purchase · Acquired 1,000 · Balance 1,012 |
| Common StockSEC Table I · non-derivative | IndirectMunera Family Trust | 34 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 34 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Mar 17, 2026 21:44 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | PurchaseCommon Stock | 1,000 | $1.27 | $1,270.00 |
DisclosureSEC source: 0001493152-26-010630 · ownership.xml · nonDerivative · entry 1 Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,012 Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000704 · ownership.xml · derivative · entry 1 Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 23:56 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001654954-25-000411 · section16.xml · derivative · entry 1 Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 02:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001654954-24-000290 · section16.xml · derivative · entry 1 Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12-month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12-month anniversary of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001654954-23-000148 · section16.xml · derivative · entry 1 Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 23:59 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000905718-22-000038 · dermata_fm4jan32022.xml · derivative · entry 1 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionWarrant to Purchase Common Stock · Derivative | 4,878 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 13 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 4,878 Underlying: Common Stock · 4,878 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1a Warrants · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 12 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 0 Underlying: Common Stock · 4,878 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1 Preferred Stock · Derivative | 280,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 11 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 0 Underlying: Common Stock · 13,658 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. F5 · derivative.exercise_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. F5 · derivative.expiration_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1c Preferred Stock · Derivative | 357,142 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 10 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 0 Underlying: Common Stock · 17,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. F4 · derivative.exercise_date: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. F4 · derivative.expiration_date: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1b Preferred Stock · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 9 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 0 Underlying: Common Stock · 4,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. F3 · derivative.exercise_date: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. F3 · derivative.expiration_date: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1a Preferred Stock · Derivative | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 8 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 0 Underlying: Common Stock · 19,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. F2 · derivative.exercise_date: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. F2 · derivative.expiration_date: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1d Preferred Stock · Derivative | 61,821 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 7 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 0 Underlying: Common Stock · 9,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. F1 · derivative.exercise_date: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. F1 · derivative.expiration_date: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 13,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 5 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 84,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 17,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 4 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 70,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 4,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 3 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 53,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 19,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 2 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 48,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:51 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 9,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 1 Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Munera Family Trust Disclosed balance after: 28,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.